Parenteral Drugs (India) (NSE:PDPL) Interest Expense: ₹-1,062.47 Mil (TTM As of Mar. 2022)


NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) Interest Expense?

Parenteral Drugs (India) NSE:PDPL 4 Interest Expense is ₹-1,062.47 Mil as of Mar. 2022. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Parenteral Drugs (India)'s interest expense for the three months ended in Mar. 2022 was ₹ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2022 was ₹-1,062.47 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Parenteral Drugs (India)'s Operating Income for the three months ended in Mar. 2022 was ₹ -330.39 Mil. Parenteral Drugs (India)'s Interest Expense for the three months ended in Mar. 2022 was ₹ -0.01 Mil. Parenteral Drugs (India) did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Parenteral Drugs (India)  (NSE:PDPL) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Parenteral Drugs (India)'s Interest Expense for the three months ended in Mar. 2022 was ₹-0.01 Mil. Its Operating Income for the three months ended in Mar. 2022 was ₹-330.39 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2022 was ₹1,071.99 Mil.

Parenteral Drugs (India)'s Interest Coverage for the quarter that ended in Mar. 2022 is calculated as

Parenteral Drugs (India) did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Parenteral Drugs (India) Interest Expense Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Interest Expense Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -958.31 -960.39 -1,099.51 -1,254.37 -1,062.47

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -324.61 -340.97 -354.65 -366.83 -0.01
NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-1,062.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of ₹-1,062.47 Mil mean?
Parenteral Drugs (India) (NSE:PDPL) has a Interest Expense of ₹-1,062.47 Mil as of Mar. 2022. Interest Expense is the amount a company pays on its long-term debt. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s Interest Expense too high?
Parenteral Drugs (India)'s current Interest Expense is ₹-1,062.47 Mil. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s Interest Expense compare to ZTS and CTLT?
Parenteral Drugs (India)'s Interest Expense of ₹-1,062.47 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Parenteral Drugs (India) and its competitors. Parenteral Drugs (India)'s current Interest Expense is ₹-1,062.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current Interest Expense of ₹-1,062.47 Mil. The current Interest Expense is ₹-1,062.47 Mil. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current Interest Expense is ₹-1,062.47 Mil as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price